Determine the commercialization potential of your lifescience technology pipeline with a TechSelect Portfolio Analysis.

Often a medical device company, lifescience accelerator or academic institution has numerous technologies incubating in the product pipelines. Executives, corporate leadership and especially potential investors, benefit from being able to reliably predict those technologies with greatest probability to deliver the highest return-on-investment (ROI). This can be a challenging responsibility when the range of technologies is wide and could include several medical devices from the least complex Class 2 diagnostic to the more clinically robust Class 3 implantable, and biologics or pharmaceutical compounds, all indicated for a broad array of clinical applications. This challenge is further elevated when many of the varying medical technologies are at different development stages.

Deciding where to allocate scarce fiscal and staffing resources requires prioritizing the technologies in more business terms to those with projected higher returns between disparate innovations.  This often comes to a head when patenting dollars need to be allocated, requiring vetting the best projects to receive the funds.  Securing objective third party guidance about which technologies are projected to deliver the greatest reward through a collaborative and cost-effective process against robust metrics is often the solution.

The TechSelect Portfolio Analysis combines primary and secondary research to determine metrics that can be the basis for comparison across all considered technologies. In addition, captured diligence includes interviews of the development teams to confirm the trajectory of each innovation and can include additional key opinion leader interviews as a cross reference, peer reviewed literature analysis, competitive landscape analysis and market analysis, woven together with established and proven business threads.

This comprehensive data collection provides, the ability to deliver a quantitative comparison among varying medical technologies, revealing those that show the most promise for commercialization.

The TechSelect Portfolio Analysis projects the following:

• Clinical adoption of a medical device, pharmaceutical, combination product or biologic
• Commercial interest in the technology at different development stages
• Competitive advantages of the evaluated technologies
• Drivers and barriers to the technology adoption
• Projected commercialization risk
• Anticipated development time to commercialization